| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
133 |
| Employees |
2,040 |
| Revenues (TTM) (Millions $) |
664 |
| Net Income (TTM) (Millions $) |
-71 |
| Cash Flow (TTM) (Millions $) |
-95 |
| Capital Exp. (TTM) (Millions $) |
33 |
Business Description
due to regulatory issues, the acquisition was terminated in 2018. Despite numerous legal battles, Akorn has continued to grow its business and expand its portfolio.
In terms of manufacturing capacity, Akorn has numerous state-of-the-art facilities located in the United States, China, India, and Switzerland. Its production facilities are compliant with the strictest quality and safety standards set by various international regulatory bodies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO).
Akorn has also established a strong global distribution network, partnering with leading distributors and wholesalers to ensure timely delivery of its products to customers and patients worldwide. The company has a dedicated team of professionals who are committed to providing high-quality products, outstanding customer service, and delivering effective medical solutions to address the evolving needs of the market.
Overall, Akorn is a leading global pharmaceutical company with a strong brand name, diverse product portfolio, state-of-the-art manufacturing facilities, and a robust global distribution network. The company remains committed to delivering innovative, high-quality, and cost-effective healthcare solutions to healthcare professionals, patients, and the animal health industry worldwide.
Company Address: 1925 W. Field Court, Lake Forest, 60045 IL
Company Phone Number: 279-6100 Stock Exchange / Ticker: AKRXQ
|
%
4.69%